CN103622915A - Targeting nanometer drug delivery system aiming at glioma - Google Patents
Targeting nanometer drug delivery system aiming at glioma Download PDFInfo
- Publication number
- CN103622915A CN103622915A CN201210306978.1A CN201210306978A CN103622915A CN 103622915 A CN103622915 A CN 103622915A CN 201210306978 A CN201210306978 A CN 201210306978A CN 103622915 A CN103622915 A CN 103622915A
- Authority
- CN
- China
- Prior art keywords
- delivery system
- glioma
- polyethylene glycol
- cerebral glioma
- targeted nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010018338 Glioma Diseases 0.000 title claims abstract description 47
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 44
- 230000008685 targeting Effects 0.000 title abstract description 8
- 238000012377 drug delivery Methods 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 26
- 239000002105 nanoparticle Substances 0.000 claims abstract description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 15
- 239000002539 nanocarrier Substances 0.000 claims abstract description 10
- 229920000642 polymer Polymers 0.000 claims abstract description 6
- 239000000693 micelle Substances 0.000 claims abstract description 5
- 239000002502 liposome Substances 0.000 claims abstract description 3
- 239000002047 solid lipid nanoparticle Substances 0.000 claims abstract description 3
- 230000002490 cerebral effect Effects 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 10
- 102000003815 Interleukin-11 Human genes 0.000 claims description 6
- 108090000177 Interleukin-11 Proteins 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 229940074383 interleukin-11 Drugs 0.000 claims description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 241000863480 Vinca Species 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 150000004056 anthraquinones Chemical class 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000001348 anti-glioma Effects 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 abstract description 2
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 abstract description 2
- -1 polymeric vesicles Polymers 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000003816 Interleukin-13 Human genes 0.000 abstract 1
- 108090000176 Interleukin-13 Proteins 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 26
- 230000006907 apoptotic process Effects 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 13
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 10
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 240000002853 Nelumbo nucifera Species 0.000 description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000024055 brain glioblastoma Diseases 0.000 description 5
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000375 Poly(ethylene glycol)-block-poly(ε−caprolactone) methyl ether Polymers 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000029824 high grade glioma Diseases 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000012764 semi-quantitative analysis Methods 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000007983 brain glioma Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- RAUPFUCUDBQYHE-AVGNSLFASA-N Asn-Phe-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RAUPFUCUDBQYHE-AVGNSLFASA-N 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WRNAXCVRSBBKGS-BQBZGAKWSA-N Glu-Gly-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O WRNAXCVRSBBKGS-BQBZGAKWSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 1
- 101150027484 ILI3 gene Proteins 0.000 description 1
- SJIGTGZVQGLMGG-NAKRPEOUSA-N Ile-Cys-Arg Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)O SJIGTGZVQGLMGG-NAKRPEOUSA-N 0.000 description 1
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 102200000740 rs193922744 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to the field of medicine preparation, and in particular to a targeting nanometer drug delivery system aiming at glioma, and a preparation method and application thereof. The drug delivery system comprises target functional molecules, a drug and nano carriers. The target functional molecules are from short chain polypeptide from interleukin 13; the drug is a micromolecular anti-glioma drug; the nano carriers are liposome with surface modified by polyethylene glycol, nanoparticles, polymeric vesicles, polymer micelles and solid lipid nanoparticles; and the drug is enveloped in the nano carriers in an enveloping or covalent connection manner, and the short chain polypeptide is connected with the polyethylene glycol on the surfaces of the nanoparticles through covalent connection. The drug delivery system can promote uptake of the glioma cells by mediated effect of an interleukin 13 receptor alpha 2 on the surfaces of the glioma cells, so as to improve the effect of anti-glioma chemotherapeutics.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to cancer target and pass medicine research, be specifically related to a kind of targeted nano delivery system for cerebral glioma and its preparation method and application.
Background technology
Malignant glioma has become affects one of the brain of human health major disease, report according to statistics, and it has very high mortality rate, and 5 years survival rates of adult's malignant glioma are lower than 5%, but there is no at present the way of effective healing.For malignant glioma, traditional Therapeutic Method is to adopt antitumor drug to carry out chemotherapy after ocal resection again.Yet excision is very risky, and most of traditional antitumor drug does not have selectivity, when killing tumor cell, can cause lethal effect to normal cell yet, causes serious side effect and its application is restricted.
At present, nano target delivery system is one of focus of antitumor drug research and development.The antitumor research of nanoscale medicine delivery system is devoted in a large amount of research and invention, to improve the antitumous effect of medicine, reduces the toxic and side effects of medicine.As patent " nano-micelle preparations of the anthracene nucleus antineoplastic antibiotic that polyglycol derivatization phospholipid bag carries " (number of patent application 200510059621.8), " nano-micelle preparations of the catharanthus roseus alkaloids anti-tumor medicaments that polyglycol derivatization phospholipid bag carries " (number of patent application 200510098381.2), " preparation method that suppresses the composite nano-polymers of multi-drug resistance of the tumor " (number of patent application 200610096365.4), " a kind of tumour-specific targeting drug delivery system and the application in preparing medicine for treating tumor thing thereof " (number of patent application 02105456.8).And, the preparation listing of existing part nano target delivery system, as Evacet, paclitaxel albumin nano granular.Nano target delivery system treatment tumor main advantage is embodied in following 2 points: first, nanoscale medicine delivery system is by the distribution that enhancing sees through and delay (EPR) effect has improved tumor locus of tumor locus, reduced the distribution of non-target site, improve the action effect of medicine, reduced the toxic and side effects of medicine; Second, some normal cell of the normal specificity overexpression of tumor cell surface is not expressed or receptor or the albumen of low expression, on nanoscale medicine delivery system surface, connect a target function molecule, the combination of the specific receptor by target function molecule and tumor cell surface, can significantly improve tumor cell for the picked-up of medicine, improve the antitumous effect of nanoscale medicine delivery system.
Prior art discloses Interleukin-13 receptor I α 2(L13R α 2) be interleukin-11 3(IL13) one of receptor, on kinds of tumor cells surface, have specific expressedly, there is very high affinity with interleukin-11 3.Research discovery, the expression of IL23R α 2 has significant samples of human glioma specificity: only express the glioma in astrocyte source, and normal brain tissue cell is not expressed or trace is expressed; And IL13R α 2 is relevant to the grade of malignancy of astrocytoma, and have closely related with the generation development of astrocytoma.Therefore, IL13R α 2 is considered to new glioma mark of correlation thing, can be used for targeting diagnosis and the treatment of glioma.There is research to confirm IL13 and toxic protein molecule construction fusion rotein, by IL13R α 2 combinations of IL13 and tumor surface, lps molecule targeting is imported in tumor cell, play the effect of killing tumor cell.As people IL13 and Pseudomonas exotoxin (PE) are formed to fusion rotein IL13PE38QQR, IL13PE38QQR just can kill glioma cell in extremely low concentration, and its toxic action can be blocked by excessive IL13, the cytotoxic effect of prompting IL13R α 2 mediations is special.Because normal brain tissue cell is expressed IL13R α 2 hardly, so IL13PE38QQR does not show obvious toxicity or there is no toxicity these cells.Pharmacodynamics test also confirms, IL13PE38QQR has good therapeutic effect to lotus glioblastoma Mus, does not find obvious toxic and side effects.Due to the acquired clinical front experimental result preferably of IL13PE38QQR, be used to I/II clinical and experimental study of the glioblastoma patient of recurrence.
Although it is the method for approving in the industry that construction of fusion protein is realized the targeted therapy of glioma, remain in following shortcoming: (1) fusion rotein may reduce the affinity of IL13 and IL13R α 2, also likely reduce the activity of toxin protein simultaneously; (2) stably express of fusion rotein and purification difficulty are large, and production cost is high; (3) receptor of IL13 is more, fusion rotein may targeting non-target site cell, cause the toxic and side effects of normal tissue cell; (4) the quiet notes Half-life in vivo of fusion rotein is short, and medicine is less in the distribution of tumor locus.IL13 peptide (sequence is VDKLLLHLKKLFREGQFNRNFESIIICRDR) is the short peptide sequence that derives from IL13, has very high affinity with IL13R α 2, and is not combined with other receptor of IL13.Have no at present the report of IL13 peptide decorated nanometer delivery system treatment cerebral glioma both at home and abroad.
For obtaining better glioma targeting, significantly improve tumor cell for the picked-up of medicine, improve the antitumous effect of medicine.The present invention intends adopting IL13 peptide decorated nanometer delivery system, by the IL13R α 2 on selectively targeted glioma cell surface, promotes the picked-up of tumor cell, improves the antitumous effect of chemotherapeutics.
Summary of the invention
The object of the invention is to the deficiency existing for prior art, a kind of nanoscale medicine delivery system for cerebral glioma is provided, be specifically related to the nanoscale medicine delivery system that IL13 peptide is modified.This delivery system can pass through the mediation of brain glioblastoma cell surface receptor IL13R α 2, promotes the picked-up of tumor cell, improves the antitumous effect of chemotherapeutics.
Particularly, it is characterized in that, comprise target function molecule, medicine and nano-carrier, described target function molecule is the small peptide (IL13) that derives from interleukin-11 3, described medicine is micromolecule antitumor drug, and described nano-carrier is polyethyleneglycol modified liposome, nanoparticle, polymer vesicle, polymer micelle or solid lipid nanoparticle of surface; Described medicine is loaded in nano-carrier with parcel or covalently bound mode bag, and described small peptide is connected with the Polyethylene Glycol on nanoparticle surface by covalently bound mode.
In the present invention, the described small peptide aminoacid sequence that derives from IL13 is VDKLLLHLKKLFREGQFNRNFESIIICRDR.
In the present invention, the molecular weight of nano-carrier surface Polyethylene Glycol is 1000-20000Da, preferably 2000-5000Da; Above-mentioned Polyethylene Glycol can be mono methoxy polyethylene glycol, or contains the Polyethylene Glycol of other active group; Above-mentioned active group is selected from a kind of in maleimide base, sulfydryl, amido, carboxyl, biotin or Avidin.
In the present invention, described targeted nano delivery system particle diameter is 10-300nm, preferably 50-150nm.
In the present invention, micromolecule antitumor drug is selected from a kind of in taxanes, Anthraquinones, camptothecin, vinca.
Object of the present invention is achieved through the following technical solutions:
1, take polyethylene glycol-caprolactone (PEG-PCL) is material, adopt the preparation of emulsifying lyase evaporation to carry Docetaxel nanoparticle (DTX-NP), IL13 peptide is connected and obtains DTX-ILNP with carboxyl-PEG covalency on nanoparticle surface, Zeta/ laser particle analyzer is measured mean diameter and the current potential of nanoparticle, its form of transmission electron microscope observing;
2, external glioma cell apoptosis test, the targeted therapy effect of the drug-carrying nanometer particle that cellular level evaluation IL13 peptide is modified to glioma cell;
3, by external glioma ball growth inhibited, test the therapeutic effect of the drug-carrying nanometer particle that evaluation IL13 peptide is modified to external glioma ball;
4, with after IR dyes Dir marking nano grain, the targeting of the nanoparticle of evaluating the modification of IL13 peptide by living imaging to cerebral glioma;
5, by anti-glioma in body, test the therapeutic effect of the drug-carrying nanometer particle that evaluation ILI3 peptide is modified to lotus glioma Mus.
Outstanding advantages of the present invention is that this delivery system, by the mediation of brain glioblastoma cell surface Interleukin-13 receptor α 2, promotes the picked-up of brain glioblastoma cell, effectively realizes the targeted therapy of cerebral glioma, improves the anti-cerebral glioma effect of chemotherapeutics.
For the ease of understanding, below the drawings and Examples by concrete are described in detail the cerebral glioma targeted nano delivery system of IL13R α 2 mediations of the present invention.It needs to be noted, instantiation and accompanying drawing are only in order to illustrate, those of ordinary skill in the art can make various corrections and change to the present invention within the scope of the invention according to explanation herein, and these corrections and change are also included in scope of the present invention.
Accompanying drawing explanation
Fig. 1, the structure of nanoparticle and sign, wherein, (A) transmission electron microscope picture; (B) particle size distribution figure.
Fig. 2, the ILNP that carries DTX suppresses external U87 tumor ball growth figure, wherein, (A) tumor sphere volume-time graph; (B) the shape of tumor figure after drug treatment; DTX concentration 2500ng/mL, Control is administration matched group not, DTX is free Docetaxel group, NP is for carrying a DTX nanoparticle group, ILNP be IL13 peptide modify carry DTX nanoparticle group,
ap<0.05 and matched group comparison;
bp<0.05 and DTX group are relatively;
cp<0.05 and NP group are relatively.
Fig. 3, the live body scattergram of targeted nano granule in lotus glioma nude mouse, wherein, (A) living imaging figure; (B) blood, organ fluorescence imaging figure; (C) brain fluorescence intensity semi-quantitative analysis result figure; (D) organ fluorescence intensity semi-quantitative analysis result figure; (E) cerebral tumor position fluorescence intensity semi-quantitative analysis result figure.
Fig. 4, targeted nano delivery system treatment lotus glioma animal model effect, wherein, (A) is the survival curve of tumor bearing nude mice; (B) (green fluorescence granule represents nucleus apoptosis to TUNEI apoptosis colored graph, and blue markings is nucleus; Experiment divides four groups: normal saline (Saline) group, DTX group, NP group and ILNP group.
The specific embodiment
Preparation and the sign of embodiment 1 IL13 peptide decorated nanometer grain (ILNP)
Adopt emulsifying lyase evaporation to prepare nanoparticle, accurately weigh 1.0mgDTX, 28.0mg methoxyl group-PEG-PCL, 2.0mg carboxyl-PEG-PCL, is dissolved in after 1ml dichloromethane, the sodium cholate that adds 5ml0.6 ﹪, under ice-water bath, ultrasonic 5s, stops 5s, totally 20 times, 37 ℃ revolve steaming 15min removal dichloromethane, and 3500rpm4 ℃ of centrifugal ultrafiltration is concentrated into 1mL.With MES (MES) buffer (pH6.0), cross the desalination of Hitrap desalting column the outer water of displacement, add 4mg1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (EDC) and 6mgN-N-Hydroxysuccinimide (NHS) to activate 20 minutes, crossing the desalination of Hitrap desalting column and replacing outer water is 0.01 mol/L phosphate buffer (PBS, pH7.4).Add 20 μ gIL13 peptides, reaction 6h, crosses Sepharose CL-4B post and washes punching, removes unconjugated ILl3 peptide, obtains year DTX nanoparticle (ILNP) that ILl3 peptide is modified.Adopt particle size analyzer to measure particle diameter and the Zete current potential of nanoparticle, after 1% (w/V, pH 7.0) phosphotungstic acid negative staining, transmission electron microscope observing particle shape.As shown in Figure 1, ILNP form rounding, mean diameter 124.5 nm, surperficial Zeta potential is-2.44 mV.
The external glioma cell apoptosis test of embodiment 2
U87 cell is seeded to 6 cm culture plates and cultivates 24 hours, the ILNP that to add containing DTX concentration after cell degree of converging reaches 80% left and right be 500ng/mL cultivates 24 hours.By cell dissociation, adopt apoptosis detection kit (containing annexinV-FITC and propidium iodide 50 μ g/mL) to dye to cell, flow cytometry detects morning, the late period apoptosis rate of cell.It is as shown in table 1 that flow cytometry detects apoptosis result, matched group U87 cell early, late period apoptosis seldom.Compare with matched group, after NP, ILNP, DTX process cell early, late period apoptosis rate all have remarkable increase, the total apoptosis rate of cell significantly increases, wherein, NP, ILNP group process after total apoptosis rate of cell be all significantly higher than DTX group.Table 1 is U87 apoptosis rate (n=3).
Table 1
*p<0.05, compared with the control;
compare with DTX group.
Embodiment 3 vitro inhibition U87 tumor ball growth tests
U87 cell is seeded to 6 well culture plates that have been coated with agarose and cultivates 7 days, make it to be grown to serve as without vascular tumor ball.To add containing DTX concentration be 2500ng/mL, and ILNP cultivates 5 days, measures tumor sphere volume every day, and while take administration, initial tumor sphere volume is with reference to the change in volume of calculating tumor ball.After treatment finishes, tumor ball is fixed to the configuration of surface of scanning electron microscopic observation tumor ball with 2.5% glutaraldehyde.Result as shown in Figure 2 A, the growth of matched group tumor ball is very fast, compares with matched group, and after NP, ILNP, DTX process, the growth of tumor ball is subject to obvious inhibition, the tumor sphere volume of ILNP group, significantly lower than NP and DTX group, shows that ILNP tool is with suppressing preferably tumor ball growth.Scanning electron microscope result also shows, matched group tumor sphere volume is larger, smooth surface, and cellular morphology is complete, clear to be debated.After adopting NP or DTX to process, tumor sphere volume diminishes, and surface is comparatively smooth, but cellular morphology is imperfect, has as seen obvious cell rupture.After adopting ILNP to process, tumor sphere volume is minimum, rough surface, and cellular morphology is imperfect, has obvious cell rupture, can obviously observe coming off of tumor cell.Prompting ILNP can inducing tumor cell apoptosis, suppress the growth of tumor ball.
Set up lotus U87 Brain Glioma Model, with nir dye Dir marking nano grain, by after 10 μ g/kg dosage tail intravenously administrables respectively at 2h, 4h, 8h, 12h, 24h detects nanoparticle in the picked-up at cerebral glioma position, the rear execution thing of administration 24, get each major organs, fluorescence imaging in living imaging instrument, as shown in Fig. 3 result, the fluorescence intensity of the nanoparticle that ILNP modifies at cerebral glioma position is significantly higher than the nanoparticle NP of unmodified, in animal level, confirmed that being modified with of target function molecule I L13 peptide helps nanoparticle and be distributed to cerebral glioma position.
The anti-cerebral glioma pharmacodynamic experiment of embodiment 5
The nude mice of lotus cerebral glioma is divided into four groups at random, is labeled as normal saline group (Saline), free Docetaxel group (DTX), carry Docetaxel nanoparticle group (NP), carry Docetaxel targeted nano granule group (ILNP), plant tumor and within 8 days, press afterwards DTX 10mg/Kg administration, within every 3 days, be administered once, totally four times (the 8th, 11,14,17 days), observe the survival curve of animal, calculate the median survival interval of each treatment group, take matched group as reference, calculate the median survival interval rate elongation of each treatment group.Kind of tumor after 20 days every group get at random 2 animals, put to death and to get brain, dehydration after 10 ﹪ neutral formalins are fixed 24 hours, frozen section after OCT embedding, TUNEL test kit detects apoptosis situation.
As shown in Fig. 4 and table 2, after administration, the death of matched group mice with tumor is the fastest, and after kind tumor, in 30 days all dead (Fig. 4 A), its median survival time is 23.0 days (table 2).Adopt DTX and NP treatment, can significantly delay the death (Fig. 4 A) of mice with tumor, its median survival time is respectively 30.0,35.0 days (table 2).Adopt ILNP treatment can significantly delay the death of mice with tumor, its median survival time is 42.0 days, is significantly higher than DTX and NP group.As shown in Figure 4 B, the dyeing of TUNEL apoptosis shows, the unobservable obvious apoptosis of brain glioblastoma cell of normal saline group, NP and DTX group brain glioblastoma cell have a small amount of apoptosis, and apoptosis of tumor cells degree is significantly higher than NP and DTX group after ILNP treatment, consistent with survival curve result.Above result shows, IL13 peptide can increase specifically DTX and make tumor suppression effect obviously be better than other each groups accumulating of cerebral glioma position.
The median survival time of table 2. mice with tumor (n=6)
ap<0.05 compared with the control,
bp<0.05 compares with DTX group,
cp<0.05 compares with NP group.
SEQUENCE LISTING
<110> Fudan University
<120> targeted nano delivery system for cerebral glioma
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 30
<212> PRT
<213> derives from the small peptide of interleukin-11 3
<400> 1
Val Asp Lys Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly Gln
1 5 10 15
Phe Asn Arg Asn Phe Glu Ser Ile Ile Ile Cys Arg Asp Arg
20 25 30
Claims (8)
1. the targeted nano delivery system for cerebral glioma, it is characterized in that, comprise target function molecule, medicine and nano-carrier, described target function molecule is the small peptide that derives from interleukin-11 3, described medicine is micromolecule antitumor drug, and described nano-carrier is polyethyleneglycol modified liposome, nanoparticle, polymer vesicle, polymer micelle or solid lipid nanoparticle of surface; Described medicine is loaded in nano-carrier with parcel or covalently bound mode bag, and described small peptide is connected with the Polyethylene Glycol on nanoparticle surface by covalently bound mode.
2. by the targeted nano delivery system for cerebral glioma claimed in claim 1, it is characterized in that, described its aminoacid sequence of the small peptide that derives from interleukin-11 3 is:
VDKLLLHLKKLFREGQFNRNFESIIICRDR。
3. by the described targeted nano delivery system for cerebral glioma of claim 1, it is characterized in that, the molecular weight of described Polyethylene Glycol is 1000-20000Da.
4. by the described targeted nano delivery system for cerebral glioma of claim 1, it is characterized in that, the molecular weight of described Polyethylene Glycol is 2000-5000Da.
5. by the targeted nano delivery system for cerebral glioma of claim 1, it is characterized in that, described Polyethylene Glycol is mono methoxy polyethylene glycol or the Polyethylene Glycol that contains other active group.
6. by the targeted nano delivery system for cerebral glioma of claim 5, it is characterized in that, described active group is selected from a kind of in maleimide base, sulfydryl, amido, carboxyl, biotin or Avidin.
7. by the targeted nano delivery system for cerebral glioma of claim 1, it is characterized in that, described targeted nano delivery system particle diameter is 10-300nm.
8. by the targeted nano delivery system for cerebral glioma claimed in claim 1, it is characterized in that, the anti-cerebral glioma medicine of described micromolecule is selected from a kind of in taxanes, Anthraquinones, camptothecin or vinca.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210306978.1A CN103622915B (en) | 2012-08-24 | 2012-08-24 | A kind of targeted nano delivery system for cerebral glioma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210306978.1A CN103622915B (en) | 2012-08-24 | 2012-08-24 | A kind of targeted nano delivery system for cerebral glioma |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103622915A true CN103622915A (en) | 2014-03-12 |
CN103622915B CN103622915B (en) | 2015-10-07 |
Family
ID=50204606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210306978.1A Expired - Fee Related CN103622915B (en) | 2012-08-24 | 2012-08-24 | A kind of targeted nano delivery system for cerebral glioma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103622915B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105497922A (en) * | 2014-09-25 | 2016-04-20 | 复旦大学附属华山医院 | Targeted nano-magnetic resonance contrast agent for brain epileptic foci, preparation and application thereof |
CN105582539A (en) * | 2014-10-20 | 2016-05-18 | 复旦大学 | Drug delivery system for glioma cell and dependent vessel |
CN105582540A (en) * | 2014-10-20 | 2016-05-18 | 复旦大学 | Brain glioma targeting drug delivery system by aiming at fatty acid-binding protein acceptor |
CN106619571A (en) * | 2017-01-03 | 2017-05-10 | 西南交通大学 | Polymer nanocarrier capable of promoting endocytosis and cell nucleus targeting and preparation method of polymer nanocarrier |
CN108126189A (en) * | 2018-02-12 | 2018-06-08 | 中国药科大学 | It is classified nano combined carrier delivery system and its application of assembling |
CN110354096A (en) * | 2019-07-03 | 2019-10-22 | 中国人民解放军第四军医大学 | Have both the brain targeting drug delivery system for improving drug resistance glioma microenvironment and reversing drug resistance |
WO2019237884A1 (en) * | 2018-06-14 | 2019-12-19 | 复旦大学 | AMYLOID β SHORT PEPTIDE MEDIATED BRAIN TARGETED DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOF |
CN111956367A (en) * | 2020-09-18 | 2020-11-20 | 上海中医药大学 | Nano drug delivery system for treating brain tumor |
CN113384707A (en) * | 2021-07-16 | 2021-09-14 | 高州市人民医院 | Preparation method of novel nano preparation capable of treating brain glioma |
CN113480603A (en) * | 2021-07-13 | 2021-10-08 | 四川大学 | Specific short peptide targeting glioma cells, coding gene and application thereof |
CN116869968A (en) * | 2023-09-07 | 2023-10-13 | 四川大学 | Nanoparticulate targeting brain and brain glioma, and synthesis method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009045579A2 (en) * | 2007-06-14 | 2009-04-09 | The Regents Of The University Of California | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
CN101588816A (en) * | 2006-10-19 | 2009-11-25 | 默克制药公司 | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
-
2012
- 2012-08-24 CN CN201210306978.1A patent/CN103622915B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101588816A (en) * | 2006-10-19 | 2009-11-25 | 默克制药公司 | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
WO2009045579A2 (en) * | 2007-06-14 | 2009-04-09 | The Regents Of The University Of California | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
Non-Patent Citations (2)
Title |
---|
俞文桥等: "人脑胶质瘤特异抗原肽白介素13α2受体的原核表达", 《中国肿瘤临床》, vol. 38, no. 9, 31 December 2011 (2011-12-31), pages 488 - 491 * |
张振宇: "纳米载体系统治疗恶性胶质瘤研究进展", 《国际精神病学神经外科学杂志》, vol. 38, no. 3, 31 December 2011 (2011-12-31) * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105497922A (en) * | 2014-09-25 | 2016-04-20 | 复旦大学附属华山医院 | Targeted nano-magnetic resonance contrast agent for brain epileptic foci, preparation and application thereof |
CN105497922B (en) * | 2014-09-25 | 2018-11-16 | 复旦大学附属华山医院 | For the targeted nano mr contrast agent of brain epileptogenic focus and its preparation and application |
CN105582539A (en) * | 2014-10-20 | 2016-05-18 | 复旦大学 | Drug delivery system for glioma cell and dependent vessel |
CN105582540A (en) * | 2014-10-20 | 2016-05-18 | 复旦大学 | Brain glioma targeting drug delivery system by aiming at fatty acid-binding protein acceptor |
CN105582539B (en) * | 2014-10-20 | 2019-01-11 | 复旦大学 | It is a kind of for glioma cell and its rely on blood vessel drug delivery system |
CN106619571A (en) * | 2017-01-03 | 2017-05-10 | 西南交通大学 | Polymer nanocarrier capable of promoting endocytosis and cell nucleus targeting and preparation method of polymer nanocarrier |
CN108126189A (en) * | 2018-02-12 | 2018-06-08 | 中国药科大学 | It is classified nano combined carrier delivery system and its application of assembling |
CN108126189B (en) * | 2018-02-12 | 2021-03-02 | 中国药科大学 | Nano composite carrier drug delivery system assembled in grading manner and application thereof |
WO2019237884A1 (en) * | 2018-06-14 | 2019-12-19 | 复旦大学 | AMYLOID β SHORT PEPTIDE MEDIATED BRAIN TARGETED DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOF |
CN110604821A (en) * | 2018-06-14 | 2019-12-24 | 复旦大学 | Brain targeting delivery system mediated by amyloid beta short peptide |
CN110354096A (en) * | 2019-07-03 | 2019-10-22 | 中国人民解放军第四军医大学 | Have both the brain targeting drug delivery system for improving drug resistance glioma microenvironment and reversing drug resistance |
CN111956367A (en) * | 2020-09-18 | 2020-11-20 | 上海中医药大学 | Nano drug delivery system for treating brain tumor |
CN113480603A (en) * | 2021-07-13 | 2021-10-08 | 四川大学 | Specific short peptide targeting glioma cells, coding gene and application thereof |
CN113480603B (en) * | 2021-07-13 | 2022-03-01 | 四川大学 | Specific short peptide targeting glioma cells, coding gene and application thereof |
CN113384707A (en) * | 2021-07-16 | 2021-09-14 | 高州市人民医院 | Preparation method of novel nano preparation capable of treating brain glioma |
CN116869968A (en) * | 2023-09-07 | 2023-10-13 | 四川大学 | Nanoparticulate targeting brain and brain glioma, and synthesis method and application thereof |
CN116869968B (en) * | 2023-09-07 | 2023-11-24 | 四川大学 | Nanoparticulate targeting brain and brain glioma, and synthesis method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103622915B (en) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103622915B (en) | A kind of targeted nano delivery system for cerebral glioma | |
Zhao et al. | Enhancement of radiosensitization by silver nanoparticles functionalized with polyethylene glycol and aptamer As1411 for glioma irradiation therapy | |
Sun et al. | Transferrin receptor-targeted PEG-PLA polymeric micelles for chemotherapy against glioblastoma multiforme | |
Feng et al. | Self-assembly of gold nanoparticles shows microenvironment-mediated dynamic switching and enhanced brain tumor targeting | |
Chen et al. | Transferrin-modified liposome promotes α-mangostin to penetrate the blood–brain barrier | |
Luo et al. | Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-γ-glutamylglutamine)–paclitaxel nanoconjugates | |
Han et al. | Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment | |
Huang et al. | Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration | |
Han et al. | Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect | |
US9371364B2 (en) | Dual-targeted therapeutic peptide for nasopharyngeal carcinoma, nanoparticles carrying same and uses thereof | |
Shao et al. | A smart multifunctional nanoparticle for enhanced near-infrared image-guided photothermal therapy against gastric cancer | |
Wang et al. | Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy | |
CN103169982B (en) | Biological active peptide modified nano-silver and preparation method and applications thereof | |
Song et al. | Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers | |
Xu et al. | Hyaluronic acid coated liposomes Co-delivery of natural cyclic peptide RA-XII and mitochondrial targeted photosensitizer for highly selective precise combined treatment of colon cancer | |
CN107157950B (en) | Albumin nanoparticles and preparation method and application thereof | |
Zou et al. | Selenium nanoparticles coated with pH responsive silk fibroin complex for fingolimod release and enhanced targeting in thyroid cancer | |
WO2019080504A1 (en) | Cell penetrating peptide and cell penetrating peptide complex, and application thereof | |
Ma et al. | tLyP-1 peptide functionalized human H chain ferritin for targeted delivery of paclitaxel | |
Chen et al. | RETRACTED ARTICLE: The therapeutic effect of methotrexate-conjugated Pluronic-based polymeric micelles on the folate receptor-rich tumors treatment | |
KR102631204B1 (en) | VAP polypeptide and its use in manufacturing drugs for targeted diagnosis and treatment of tumors | |
Yang et al. | Subcellular co-delivery of two different site-oriented payloads for tumor therapy | |
Fan et al. | Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery | |
Nagesetti et al. | Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids | |
Liu et al. | A novel GSH responsive poly (alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151007 |